Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
In a recent expert meeting, Swedish recommendations for the treatment of HCV infection were upgraded. The panel recommends vaccination against both hepatitis A and B in patients with HCV. Therapy for symptomatic acute HCV infection should be initiated if spontaneous resolution has not occurred within 12 weeks, whereas asymptomatic acute HCV should be treated upon detection. Patients with genotype 2/3 infection should generally be treated for 24 weeks. In patients with a very rapid viral response (vRVR), i.e. HCV RNA below 1000 IU/ml on d 7, treatment can be shortened to 12-16 weeks, provided that no dose reduction has been made. For genotype 1 patients with rapid viral response (RVR), 24 weeks treatment is recommended. For patients with a complete early viral response (cEVR), 48 weeks treatment is recommended, whereas 72 weeks treatment should be considered for patients with partial early viral response (pEVR). For patients with difficult-to-treat disease and with pronounced anaemia, erythropoietin can be used to maintain the ribavirin dose. In HCV-HIV coinfected patients, combination therapy for HCV should, if possible, be initiated before anti-retroviral therapy (ART) is indicated. For liver transplant patients pre-emptive therapy is not recommended; hence, treatment should be deferred until histological recurrence.
Lagging
Martin
M
Department of Infectious Diseases and Virology, Sahlgrenska University Hospital, Göteborg. martin.lagging@medfak.gu.se
Wejstål
Rune
R
Uhnoo
Ingrid
I
Gerdén
Barbro
B
Fischler
Björn
B
Friman
Styrbjörn
S
Josephson
Filip
F
Karlström
Olle
O
Sangfelt
Per
P
Schvarz
Robert
R
Weiland
Ola
O
D000208:Acute Disease; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D013548:Sweden
D000998:Antiviral Agents; D012254:Ribavirin